ORAL01.04: Phase II Trial of Atezolizumab for Patients with PD-L1–Selected Advanced NSCLC (BIRCH): Updated Efficacy and Exploratory Biomarker Results Topic: Medical Oncology
Wakelee H, Patel J, Heist R, Balmanoukian A, Besse B, Felip E, Costa E, Chow L, Koczywas M, Garassino M, Christoph D, Toh C, Johnson M, Chaft J, Kurata T, Qiu J, Kowanetz M, Coleman S, Mocci S, Sandler A, Gettinger S, Peters S. ORAL01.04: Phase II Trial of Atezolizumab for Patients with PD-L1–Selected Advanced NSCLC (BIRCH): Updated Efficacy and Exploratory Biomarker Results Topic: Medical Oncology. Journal Of Thoracic Oncology 2016, 11: s251-s252. DOI: 10.1016/j.jtho.2016.09.009.Peer-Reviewed Original ResearchORAL01.03: CheckMate 012: Safety and Efficacy of First-Line Nivolumab and Ipilimumab in Advanced NSCLC Topic: Medical Oncology
Antonia S, Gettinger S, Goldman J, Brahmer J, Borghaei H, Chow L, Ready N, Gerber D, Juergens R, Shepherd F, Laurie S, Young T, Geese W, Agrawal S, Li X, Hellmann M. ORAL01.03: CheckMate 012: Safety and Efficacy of First-Line Nivolumab and Ipilimumab in Advanced NSCLC Topic: Medical Oncology. Journal Of Thoracic Oncology 2016, 11: s250-s251. DOI: 10.1016/j.jtho.2016.09.008.Peer-Reviewed Original ResearchPS01.62: Long-Term Safety and Clinical Activity of Atezolizumab Monotherapy in Metastatic NSCLC: Final Results from a Phase Ia Study Topic: Medical Oncology
Gordon M, Herbst R, Horn L, Soria J, Gandhi L, Felip E, Sequist L, Spigel D, Antonia S, Balmanoukian A, Cassier P, Liu B, Kowanetz M, O'Hear C, Fassò M, Sandler A, Gettinger S. PS01.62: Long-Term Safety and Clinical Activity of Atezolizumab Monotherapy in Metastatic NSCLC: Final Results from a Phase Ia Study Topic: Medical Oncology. Journal Of Thoracic Oncology 2016, 11: s309-s310. DOI: 10.1016/j.jtho.2016.09.097.Peer-Reviewed Original Research